The Journal of the American College of Cardiology published a study exploring changes in the characteristics of atrial fibrillation (AF) patients since the 2011 introduction of nonvitamin K antagonist oral anticoagulants (NOACs). Authors concluded that NOACs have been widely adopted for stroke prevention in newly diagnosed nonvalvular AF patients, however, undertreatment (no therapy or use of antiplatelet therapy only) was common in both North America and Asia. Notably, a significant proportion of new AF patients are electing to use vitamin K antagonists, a sign that warfarin will continue to have an important role for stroke prevention in AF for years to come. Read more >>>